ProShare Advisors LLC Purchases 9,280 Shares of Zoetis Inc. $ZTS

ProShare Advisors LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 8.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,677 shares of the company’s stock after buying an additional 9,280 shares during the quarter. ProShare Advisors LLC’s holdings in Zoetis were worth $15,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the fourth quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Zoetis in the 3rd quarter valued at $31,000. Lodestone Wealth Management LLC bought a new position in shares of Zoetis during the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new position in shares of Zoetis during the 4th quarter valued at $32,000. Finally, Holos Integrated Wealth LLC purchased a new position in Zoetis in the 4th quarter worth $32,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 0.9%

Shares of ZTS opened at $79.64 on Thursday. The stock has a market capitalization of $33.39 billion, a P/E ratio of 13.21, a PEG ratio of 1.29 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a fifty day simple moving average of $109.69 and a two-hundred day simple moving average of $119.37. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZTS. Stifel Nicolaus set a $105.00 price target on shares of Zoetis in a research report on Friday, May 8th. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $134.75.

Insider Buying and Selling

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 11,650 shares of company stock valued at $886,384 over the last ninety days. 0.22% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.